J Rheumatol:幼年特发性关节炎的纵向健康状况和相关预后因素

2019-03-28 xiangting MedSci原创

JIA患者在随访3年和19年后的躯体功能、健康和疼痛相似。19年后患者的健康状况也比对照组差。

这项研究旨在描述幼年特发性关节炎(JIA)患者从儿童期到成年的纵向健康状况,在19年后与对照组进行结局比较,并确定躯体功能、疼痛和躯体健康相关生活质量(HRQOL)的早期预测因子。

1995-2003年间,96名JIA患者(平均6.1±4.0岁,67%为女性)在诊断后18个月内和此后3年每6个月进行一次JIA疾病活动性指标、躯体功能、疼痛、疲劳和健康评估。平均18.9±1.5年后(平均年龄25.1±4.2岁)进行重新评估,测量身体残疾(HAQ)、疼痛、疲劳、健康(VAS)以及身心HRQOL(S-12)。

最初3年内,身体残疾得到改善(p<0.001),报告最佳健康状况的患者比例升高(p=0.013),而疼痛和疲劳没有改变。在3年和19年的随访中,患者的身体残疾、健康和疼痛水平相似,但疲劳增多(p=0.016),HAQ=0的患者数量减少(p=0.001)。19年后,患者的疼痛和躯体HRQOL比对照组差(p<0.001)。最初3年内的疼痛、活动性关节和身体残疾与19年后更多的残疾、疼痛以及更差的躯体HRQOL相关(p<0.001-0.047)。

JIA患者在随访3年和19年后的躯体功能、健康和疼痛相似,但19年后的疲劳更常见。19年后患者的健康状况也比对照组差。疼痛、活动性关节和身体残疾是不良结局的早期预测因素。

原始出处:

Anita Tollisen. Longitudinal health status from early disease to adulthood and associated prognostic factors in juvenile idiopathic arthritis. J Rheumatol. 15 March 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1894728, encodeId=73561894e28de, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Jul 26 22:25:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265940, encodeId=7aca1265940f5, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 30 04:25:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479292, encodeId=5e8814e9292e6, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sat Mar 30 04:25:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511028, encodeId=f96815110280c, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Sat Mar 30 04:25:00 CST 2019, time=2019-03-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1894728, encodeId=73561894e28de, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Jul 26 22:25:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265940, encodeId=7aca1265940f5, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 30 04:25:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479292, encodeId=5e8814e9292e6, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sat Mar 30 04:25:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511028, encodeId=f96815110280c, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Sat Mar 30 04:25:00 CST 2019, time=2019-03-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1894728, encodeId=73561894e28de, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Jul 26 22:25:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265940, encodeId=7aca1265940f5, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 30 04:25:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479292, encodeId=5e8814e9292e6, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sat Mar 30 04:25:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511028, encodeId=f96815110280c, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Sat Mar 30 04:25:00 CST 2019, time=2019-03-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1894728, encodeId=73561894e28de, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Jul 26 22:25:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265940, encodeId=7aca1265940f5, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 30 04:25:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479292, encodeId=5e8814e9292e6, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sat Mar 30 04:25:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511028, encodeId=f96815110280c, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Sat Mar 30 04:25:00 CST 2019, time=2019-03-30, status=1, ipAttribution=)]

相关资讯

Arthritis Rheumatol:先天淋巴样细胞和T细胞影响幼年特发性关节炎滑膜液中检测到的IL-17A特征

该研究证明JIA-SFMC中IL-17A特征的强度是由多种淋巴样细胞类型决定的,其中包括NCR-ILC3、IL-17A+CD4+、IL-17A+CD8+和IL-17A+γδT细胞。

Semin Arthritis Rheu:幼年特发性关节炎相关性葡萄膜炎抗炎治疗循证、跨学科指南的更新

如果局部应用低剂量糖皮质激素(≤2次/天)无效,应引入甲氨蝶呤;如果没有达到非活动性葡萄膜炎,则使用TNFα抗体(首选阿达木单抗)。

Arthritis Rheumatol:幼年特发性关节炎患者肠道内微生态的微生物组学分析

研究人员在JIA患者中发现了生态失调的证据。

Arthritis Rheumatol:使用一线重组白介素-1受体拮抗剂治疗新发全身型幼年特发性关节炎

使用rIL-1RA一线、短程单药治疗作为开始的靶向治疗是一种非常有效的策略。

J Rheumatol:幼年特发性关节炎的新分类标准:儿科风湿病国际试验组织国际共识

目前已达成国际共识,以识别使用历史JIA术语的各种同质性慢性病。

2018年《国际儿童风湿病试验组织(PRINTO)幼年特发性关节炎新分类标准专家共识(启动步骤)》中国专家解读

中国儿童免疫与健康联盟组织了部分中国专家对这一国际共识进行解读,旨在对JIA新分类提出中国专家的建议观点,并为我国以后JIA相关真实世界研究提供依据,为与国际新标准接轨提出中国专家的意见。该文仅进行忠实于英文原文的解读,JIA新的分类标准在我国的形成及运用还需要进一步研究及探讨。